Abstract 5779
Background
Drug resistance is an important clinical problem affecting the prognosis of colorectal cancer patients with initially unresectable liver metastases. The role of 5-hydroxymethylcytosine (5-hmC) in this process is still unknown.
Methods
A single-center study was conducted to enroll colorectal cancer patients with initially unresectable liver metastases at Zhongshan Hospital, Shanghai. The 5-hmC levels of each gene locus in circulating-free DNA (cfDNA) were detected using a highly sensitive sequencing method before the patient received any conversion therapy. Eight weeks after conversion therapy, patients with disease progression according to RECIST 1.1 were defined as drug-resistant group, while patients with complete response, partial response and stable disease were defined as the drug-effective group. By using the gene loci with the most significant difference of 5-hmC level, a predictive model (Logistic regression) was established based on machine-learning method. Then, we validated the model.
Results
From June 2018 to January 2019, 35 patients were enrolled, including 20 patients in drug-effective group and 15 in drug-resistant group. The predictive model was established using the first 100 significantly different gene loci and 10 loci were included in the model. The internal validation results suggested that the sensitivity (predictive accuracy for drug-resistant patients) and specificity (predictive accuracy for drug-effective patients) were 86.7% and 95.0%, respectively, and the area under the ROC curve is 0.990.
Conclusions
Our study screened the gene loci with different 5-hmC level between drug-effective and drug-resistant colorectal cancer patients with initial unresectable liver metastases. Then we established a predictive model for the efficacy of conversion therapy, although this model is still being improved and validated by enrolling more subjects.
Clinical trial identification
NCT03679039 09/18/2018.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1619 - Meta-analysis of KRAS Mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and Sideness analysis.
Presenter: Maria Romina Luca
Session: Poster Display session 2
Resources:
Abstract
2104 - Clinical implications of regorafenib-induced hypothyroidism in metastatic colorectal cancer refractory to standard therapies: A prospective evaluation
Presenter: Jwa Hoon Kim
Session: Poster Display session 2
Resources:
Abstract
2143 - Clinical impact of BRAF V600E mutations in patients (pts) with resectable solitary colorectal liver metastases (CRLM)
Presenter: Shin Kobayashi
Session: Poster Display session 2
Resources:
Abstract
3136 - Trifluridine/tipiracil in metastatic colorectal cancer: an updated multicentre real-world analysis on efficacy, safety and predictive factors.
Presenter: Chara Stavraka
Session: Poster Display session 2
Resources:
Abstract
4234 - Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab
Presenter: Eleonora Lai
Session: Poster Display session 2
Resources:
Abstract
4287 - Safety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses
Presenter: Ian Chau
Session: Poster Display session 2
Resources:
Abstract
1820 - A Phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Johanna Bendell
Session: Poster Display session 2
Resources:
Abstract
5644 - Development and validation of a metastasis-associated immune prognostic model for concurrent metastatic colorectal cancer
Presenter: Zhiwen Luo
Session: Poster Display session 2
Resources:
Abstract
5697 - Prognostic role of blood cell count-based immuno-inflammatory parameters in the Valentino trial
Presenter: Giovanni Fuca
Session: Poster Display session 2
Resources:
Abstract
4704 - Evaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 vaccine in subjects with metastatic colorectal cancer (mCRC) with a predictive biomarker
Presenter: Joleen Hubbard
Session: Poster Display session 2
Resources:
Abstract